Le Lézard
Classified in: Health
Subjects: MIN, MRR

Global Premature Ejaculation Therapeutics Market Report 2024-2029: North America and Europe Dominate the Market in 2023, APAC Emerges as the Fastest-Growing Market


DUBLIN, Dec. 8, 2023 /PRNewswire/ -- The "Global Premature Ejaculation Therapeutics Market - Focused Insights 2024-2029" report has been added to ResearchAndMarkets.com's offering.

Research_and_Markets_Logo

The global premature ejaculation therapeutics market was valued at $2,456.71 million in 2023 and is expected to reach $4,062.34 million by 2029, growing at a CAGR of 8.74%. The market growth is mainly attributed to the rising prevalence of premature ejaculation among men globally.

This report offers market size & forecast data for the global premature ejaculation therapeutics market. The revenue generated from the sale of drugs, including off-label products, is included in the report.

The revenue generated from the devices used to manage premature ejaculation, physicians' fees, and other service-related costs is excluded from the report's scope. This report provides a comprehensive and current market scenario of the global premature ejaculation therapeutics market, including the global premature ejaculation therapeutics market size, anticipated market forecast, relevant market segmentations, and industry trends.

The study considers a detailed scenario of the present global premature ejaculation therapeutics market and its market dynamics for 2024?2029. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent players operating in the market.

KEY HIGHLIGHTS

VENDORS LIST

Key Topics Covered:

1: Pe Therapeutics Market Overview

2: Pe Therapeutics Market

3: Pe Therapeutics Market Segmentation Data

4: Key Regions Overview

5: Pe Therapeutics Market Prospects & Opportunities

6: Pe Therapeutics Industry Overview

For more information about this report visit https://www.researchandmarkets.com/r/at9gdc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

SOURCE Research and Markets


These press releases may also interest you

at 01:00
April 29, 2024 First-quarter highlights Group sales amounted to EUR 4.1 billion, with comparable sales growth of 2.4%Comparable order intake -3.8%, mainly due to ChinaUSD 1.1 billion Respironics litigation settlement reached in the US...

at 00:45
4P-Pharma, a Lille-based clinical-stage startup studio focused on developing curative therapies for untreated serious diseases, announces that it has successfully secured a total capital of ?15 million in its second closing with participation from...

at 00:20
PROTEINA announced today that it has held a kickoff meeting with Professor Janghee Woo and his research team at Emory University School of Medicine in Atlanta, to begin global clinical validation of its flagship product, PPI PathFinder BCL2 Dx. PPI...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...

at 00:00
Spectrum Dynamic's customers will...

28 avr 2024
AriBio Co., Ltd. (AriBio) announced authorisation from the European Medicines Agency (EMA) for POLARIS-AD (AR1001-ADP3-US01), a global, phase 3, early Alzheimer's disease clinical trial. EMA now aligns with the U.S. Food and Drug Administration (FDA)...



News published on and distributed by: